{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:13:05Z","timestamp":1787317985222,"version":"build-2736575974"},"reference-count":44,"publisher":"Academy of Managed Care Pharmacy","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMCP"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.18553\/jmcp.2026.32.1.53","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:27:47Z","timestamp":1766572067000},"page":"53-65","source":"Crossref","is-referenced-by-count":2,"title":["Treatment patterns, health care resource utilization and costs, and clinical outcomes among older adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma"],"prefix":"10.18553","volume":"32","author":[{"given":"Liya","family":"Wang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aolin","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Valderrama","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Rahway, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Wang","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Mattera","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-Yi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanu Priya","family":"Sharan","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Upper Gwynedd, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofya","family":"Pintova","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7818","reference":[{"issue":"3","key":"r1","first-page":"229","volume":"74","author":"Bray F","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"r2","first-page":"12","volume":"74","author":"Siegel RL","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"r3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.36"},{"key":"r4","first-page":"1020","volume":"14","author":"Lago NM","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"r5","unstructured":"Howlader N, Krapcho M, Miller D, et al. SEER Cancer Statistics Review, 1975-2018, based on November 2020 SEER data submission (posted 2021). Accessed July 13, 2024. https:\/\/seer.cancer.gov\/archive\/csr\/1975_2014\/"},{"key":"r6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113495"},{"key":"r7","unstructured":"American Cancer Society. Stomach cancer survival rates (revised January 17, 2024). Accessed July 10, 2024. https:\/\/www.cancer.org\/cancer\/types\/stomach-cancer\/detection-diagnosis-staging\/survival-rates.html"},{"key":"r8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"r9","unstructured":"HERCEPTIN (trastuzumab). Prescribing information. Genentech, Inc. 2010. Accessed July 13, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/103792s5250lbl.pdf"},{"key":"r10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.004"},{"key":"r11","unstructured":"US Food and Drug Administration. FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic HER2 positive gastric or gastroesophageal junction adenocarcinoma. Accessed July 13, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-disco-burst-edition-fda-approval-keytruda-pembrolizumab-combination-trastuzumab-fluoropyrimidine"},{"key":"r12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04161-3"},{"key":"r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1466"},{"key":"r14","unstructured":"KEYTRUDA (pembrolizumab). Prescribing information. Merck Sharp & Dohme LLC; 2014. Accessed July 10, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125514s147lbl.pdf"},{"key":"r15","unstructured":"OPDIVO (nivolumab). Prescribing information. Bristol-Myers Squibb Company; 2014. Accessed July 28, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125554s132lbl.pdf"},{"key":"r16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"r17","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-020-01567-9"},{"issue":"1","key":"r18","first-page":"32","volume":"19","author":"Le DT","year":"2020","journal-title":"Clin Colorectal Cancer"},{"key":"r19","unstructured":"Chau l. Barzi A, You M, et al. Real-world effectiveness of nivolumab plus chemotherapy in patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma in the United States. Presented at: Gastrointestinal Cancers Symposium (ASCO-GI); January 18-20, 2024; San Francisco, CA, and virtual."},{"key":"r20","doi-asserted-by":"publisher","DOI":"10.5230\/jgc.2015.15.2.87"},{"key":"r21","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0977"},{"key":"r22","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-023-00378-y"},{"key":"r23","doi-asserted-by":"crossref","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program (SEER). SEER Fact Sheets. Accessed July 10, 2024. https:\/\/seer.cancer.gov\/about\/factsheets\/","DOI":"10.1093\/jncimonographs\/lgae033"},{"key":"r24","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\n                      \u00ae\n                      ) for Gastric Cancer Version 5.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"r25","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\n                      \u00ae\n                      ) for Esophageal and Esophagogastric Junction Cancers Version 5.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed February 21, 2025. To view the most recent and complete version of the guideline, go online to NCCN.org."},{"key":"r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.03.008"},{"key":"r27","doi-asserted-by":"publisher","DOI":"10.3390\/biom13050796"},{"key":"r28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02033-0"},{"key":"r29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082311"},{"key":"r30","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0436"},{"key":"r31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050799"},{"key":"r32","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2453"},{"key":"r33","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061587"},{"key":"r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.04.121"},{"key":"r35","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12204-x"},{"key":"r36","doi-asserted-by":"publisher","DOI":"10.3390\/geriatrics7050107"},{"key":"r37","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-013-0297-z"},{"key":"r38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03077"},{"key":"r39","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16071336"},{"key":"r40","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-022-00416-x"},{"key":"r41","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12103391"},{"key":"r42","unstructured":"US Food and Drug Administration. FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer. Accessed July 10, 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer"},{"key":"r43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01601"},{"key":"r44","unstructured":"Stedman MR, Doria-Rose P, Warren JL, Klabunde CN, Mariotto A. Comorbidity Technical Report. The impact of different SEER-Medicare claims-based comorbidity indexes on predicting non-cancer mortality for cancer patients. Accessed July 13, 2024. https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/considerations\/comorbidity-report.pdf"}],"container-title":["Journal of Managed Care & Specialty Pharmacy"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T10:27:55Z","timestamp":1766572075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jmcp.org\/doi\/10.18553\/jmcp.2026.32.1.53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.18553\/jmcp.2026.32.1.53"],"URL":"https:\/\/doi.org\/10.18553\/jmcp.2026.32.1.53","relation":{},"ISSN":["2376-0540","2376-1032"],"issn-type":[{"value":"2376-0540","type":"print"},{"value":"2376-1032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}